No services found
No Products found
100ug, 1MG
ProteoGenix
IgG4, kappa
Primary Antibodies
XtenCHO
Etentamig Biosimilar, also known as Anti-TNFRSF17;CD3e mAb – Research Grade, is a therapeutic antibody targeting the TNFRSF17 and CD3e proteins. This biosimilar is a promising treatment option for various diseases, including autoimmune disorders and cancers.
Etentamig Biosimilar is a monoclonal antibody, meaning it is produced by a single type of immune cell. It is a fully human antibody, meaning it is derived from human cells and has a high affinity for its target proteins. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are linked to each other by disulfide bonds, while the light chains are linked to the heavy chains by disulfide bonds as well.
Etentamig Biosimilar binds to two different proteins, TNFRSF17 and CD3e. TNFRSF17, also known as BCMA, is a receptor found on the surface of B cells. It plays a crucial role in the survival and proliferation of B cells. CD3e is a protein found on the surface of T cells and is a component of the T cell receptor complex. It is involved in the activation and function of T cells.
Etentamig Biosimilar binds to both TNFRSF17 and CD3e simultaneously, leading to the formation of a complex between the antibody and the two proteins. This complex then triggers a series of signaling events within the B and T cells, leading to their activation and subsequent immune response.
Etentamig Biosimilar has shown promising results in preclinical studies for the treatment of multiple myeloma, a type of blood cancer. It has also shown potential in the treatment of other B cell malignancies, such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
In addition to its potential in cancer treatment, Etentamig Biosimilar has also shown potential in the treatment of autoimmune disorders. By targeting both TNFRSF17 and CD3e, the antibody can modulate the immune response and potentially reduce the symptoms of autoimmune diseases.
Etentamig Biosimilar is a therapeutic antibody, meaning it is specifically designed to target a disease-causing molecule or pathway. This targeted approach reduces the risk of side effects and allows for more precise treatment. As a fully human antibody, Etentamig Biosimilar also has a lower risk of causing an immune response in patients.
TNFRSF17 and CD3e are both important therapeutic targets for various diseases. By targeting TNFRSF17, Etentamig Biosimilar can disrupt the survival and proliferation of B cells, making it a potential treatment for B cell malignancies. Targeting CD3e can modulate T cell activation and function, making it a potential treatment for autoimmune disorders.
In conclusion, Etentamig Biosimilar is a promising therapeutic antibody that targets both TNFRSF17 and CD3e. Its unique dual targeting mechanism makes it a potential treatment option for various diseases, including cancer and autoimmune disorders. With further research and clinical trials, Etentamig Biosimilar has the potential to improve the lives of patients suffering from these diseases.
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? * WB ELISA Sandwich ELISA IF IHC IP FC other
Did it work in your application? * Yes No
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Related products
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.